Cassava Sciences Stock News

Investing in the biotech sphere isn't for the faint of heart, and you should steer clear of the biotech stocks to avoid. That's because biotech stocks tend to experience wild swings in developments, s

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced plans to present a virtu

The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biote

There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.

Cassava Sciences stock is down due to questions about some of its research. A lot is riding on its late-stage clinical trials to produce favorable data.

The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as compa

With investors moving back towards a “risk-on” stance in recent months, you may think that risky stocks could lead to outsized rewards this year. Yet while more favorable economic and market condi

In the biotechnology sector, Cassava Sciences (NADSAQ: SAVA ) remains one of the top clinical-stage companies that investors are watching. Over the past one year, SAVA stock is down by less than 20% b

The biotech has declared a fresh dividend. The payout is rather atypical -- it's in the form of common stock warrants.

Shares of pharmaceutical specialist Cassava Sciences (NASDAQ: SAVA ) soared earlier Tuesday before giving up most of the gains. Nevertheless, investor enthusiasm spiked over management's decision to i

The biotech significantly modified its board of directors. Two of those incoming directors have extensive experience in the healthcare field; the other comes from the security sphere.

Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of

Cassava Sciences is a biotech company focused on developing treatments for Alzheimer's disease with its lead drug candidate, Simufilam. The company has faced allegations of data manipulation and misco

Although the general concept of stock picks for contrarian investors may be universally appealing, when it comes to the most extreme examples, most investors should probably stay away. Basically, whil

Stocks often lose much of their value as a result of controversies. Cassava Sciences is facing a raft of serious allegations from numerous parties.